COX-2 targeting Ru-arene complexes from metal-ligand synergistic enhancement strategy for breast cancer therapy.

Triple-negative breast cancer (TNBC) has been a significant therapeutic challenge, due to its aggressive and metastatic characteristics. Cyclooxygenase-2 (COX-2), which is frequently overexpressed in TNBC and implicated in tumor progression, is considered as a potent therapeutic target. In this study, we reported a novel Ru-arene complex, Ru-tol, utilizing a metal-ligand synergistic enhancement (MLSE) strategy. Toxic Ru-tol was synthesized from the non-toxic precursors aryl ruthenium azide and tolfenamic acid. Complex Ru-tol not only owned the enhanced antiproliferative performance, but also preserved the COX-2 inhibitory activity of tolfenamic acid. Ru-tol could induce the generation of intracellular reactive oxygen species (ROS), leading to the mitochondrial and nuclear damages, which ultimately results in the apoptotic and autophagic cell death. Moreover, Ru-tol significantly downregulated the expression of COX-2, matrix metalloproteinases (MMP)-2 and MMP-9, and effectively suppressed the cell migration and invasion. Ru-tol demonstrated supeior penetration capacity and antiproliferative efficacy in 3D multicellular tumor spheroids (MCTS), suggesting the potent clinical applications. This work not only demonstrated the efficiency of MLSE strategy for the development of novel anti-cancer metal-based drugs, but also presented a promising target for the TNBC treatment.

• Publication year

  2025

• Venue

  Journal of Inorganic Biochemistry

• Publication date

  2025-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.jinorgbio.2025.113044PMID 40882261
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An efficient ICD inducer based on Ir(III) cyclometalated complex for anticancer and anti-migration effects towards cisplatin-resistant cancer cells

  2025cited by this paper
• Ru(II)-Fenamic-Based Complexes as Promising Human Ovarian Antitumor Agents: DNA Interaction, Cellular Uptake, and Three-Dimensional Spheroid Models

  2025cited by this paper
• Cancer statistics, 2025

  2025cited by this paper
• Emerging COX-2 inhibitors-based nanotherapeutics for cancer diagnosis and treatment.

  2024cited by this paper
• Mitochondria-targeted ruthenium complexes can be generated in vitro and in living cells to target triple-negative breast cancer cells by autophagy inhibition.

  2024cited by this paper
• Organometallic anti-tumor agents: targeting from biomolecules to dynamic bioprocesses.

  2023cited by this paper
• An overview of advancement of organoruthenium(II) complexes as prospective anticancer agents

  2023cited by this paper
• COX-2 blocking therapy in cisplatin chemosensitization of ovarian cancer: An allicin-based nanomedicine approach

  2023cited by this paper
• Evoking Ferroptosis by Synergistic Enhancement of a Cyclopentadienyl Iridium-Betulin Immune Agonist.

  2023cited by this paper
• Efficient NIR-II Type-I AIE Photosensitizer for Mitochondria-Targeted Photodynamic Therapy through Synergistic Apoptosis-Ferroptosis.

  2023cited by this paper
• Selectively attacking tumor cells of Ru/Ir-arene complexes based on meclofenamic acid via cyclooxygenase-2 inhibition.

  2023cited by this paper
• Photodecaging of a Mitochondria-Localized Iridium(III) Endoperoxide Complex for Two-Photon Photoactivated Therapy under Hypoxia.

  2022cited by this paper
• Unlocking the potential of iridium and ruthenium arene complexes as anti-tumor and anti-metastasis chemotherapeutic agents.

  2022cited by this paper
• Fighting metallodrug resistance through alteration of drug metabolism and blockage of autophagic flux by mitochondria-targeting AIEgens

  2022cited by this paper
• Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 years

  2022cited by this paper
• Ferroptosis Photoinduced by New Cyclometalated Iridium(III) Complexes and Its Synergism with Apoptosis in Tumor Cell Inhibition.

  2021cited by this paper
• A carrier-free anti-inflammatory platinum (II) self-delivered nanoprodrug for enhanced breast cancer therapy.

  2021cited by this paper
• Biomimetic nanoparticles loading with gamabutolin-indomethacin for chemo/photothermal therapy of cervical cancer and anti-inflammation.

  2021cited by this paper
• Mitochondria-targeted Pt(IV) prodrugs conjugated with an aggregation-induced emission luminogen against breast cancer cells by dual modulation of apoptosis and autophagy inhibition.

  2021cited by this paper
• DNA-Unresponsive Platinum(II) Complex Induces ERS-Mediated Mitophagy in Cancer Cells.

  2021cited by this paper
• Multispecific Platinum(IV) Complex Deters Breast Cancer via Interposing Inflammation and Immunosuppression as an Inhibitor of COX-2 and PD-L1.

  2020cited by this paper
• Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: Recent advancement.

  2020cited by this paper
• Using bio-orthogonally catalyzed lethality strategy to generate mitochondria-targeting anti-tumor metallodrugs in vitro and in vivo

  2020cited by this paper
• Chemopreventive Properties of Tolfenamic Acid: A Mechanistic Review.

  2018cited by this paper
• Cyclooxygenase‐2 in cancer: A review

  2018cited by this paper
• Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer

  2017cited by this paper
• The prodrug platin-A: simultaneous release of cisplatin and aspirin.

  2014cited by this paper
• Organoiridium Complexes: Anticancer Agents and Catalysts

  2014cited by this paper
• Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?

  2013cited by this paper
• Autophagy-regulating small molecules and their therapeutic applications.

  2012cited by this paper
• Use of the γ-H2AX assay to monitor DNA damage and repair in translational cancer research.

  2012cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.

  2009cited by this paper
• Activity of rat cytosolic thioredoxin reductase is strongly decreased by trans-[bis(2-amino-5- methylthiazole)tetrachlororuthenate(III)]: first report of relevant thioredoxin reductase inhibition for a ruthenium compound.

  2007cited by this paper
• Synthesis, structural characterization, solution chemistry, and preliminary biological studies of the ruthenium(III) complexes [TzH][trans-RuCl4(Tz)2] and [TzH][trans-RuCl4(DMSO)(Tz)].(DMSO), the thiazole analogues of antitumor ICR and NAMI-A.

  2004cited by this paper
• Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention.

  2002cited by this paper
• Caspase-3 Is Required for DNA Fragmentation and Morphological Changes Associated with Apoptosis*

  1998cited by this paper

• No citing papers are available for this paper.